Myelodysplastic Syndromes (MDS)

Jan P. Bewersdorf, MD

Institution
Yale School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Jan Philipp Bewersdorf, MD, specializes in hematology with a focus on the treatment of myeloid malignancies, including myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia.These conditions involve the abnormal development of blood cells and can present with symptoms such as fatigue, recurrent infections, and easy bruising. In his research, Dr. Bewersdorf collaborates with laboratory-based colleagues to integrate basic research with clinical applications, aiming to uncover new therapeutic strategies for diseases of the blood and bone marrow. "While we still cannot

2025 EHA/ASCO Update: MDS and AML

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
In this webinar, Dr. Jan Bewersdorf discusses the latest research presented at EHA and ASCO on MDS and AML. This is an advanced presentation.

A 30-gene classifier distinguishes low-risk MDS HSPCs from healthy HSPCs

Original Publication Date
Article Source
External Web Content
Highlights • Single-cell RNA-sequencing performed on 16 lower-risk myelodysplastic syndrome (LR-MDS) bone marrow-derived mononuclear cells (BMMCs) • A 30-gene signature distinguishes LR-MDS hematopoietic stem and progenitor cells (HSPCs) from Healthy HSPCs • Vesicular trafficking…

Azacitidine as therapy for VEXAS syndrome

Original Publication Date
Article Source
External Web Content
How should patients with VEXAS (an acronym for vacuoles [in myeloid and erythroid precursors], E1 enzyme, X-linked, autoinflammatory, somatic) syndrome be treated? Until now, we have only had case reports and small series to guide us. In this issue of Blood, Jachiet and…

Germline and somatic genetic landscape of pediatric myelodysplastic syndromes

Original Publication Date
Article Source
External Web Content
Abstract Pediatric myelodysplastic syndromes (MDS) represent a rare group of clonal hematopoietic stem cell disorders accounting for approximately 5% of pediatric hematologic malignancies. They are characterized by ineffective hematopoiesis, cytopenia, and dysplastic changes in…
Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.